Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice

According to data from a real-world analysis presented during the 2023 ASCO Genitourinary Cancers Symposium, treatment with bone-targeting radiopharmaceutical radium-223 among patients with castration-resistant prostate cancer and bone metastases demonstrated low rates of any drug-related adverse events and side effect–associated therapy discontinuation, particularly among those receiving first-line radium-223 compared with second and third line.